Weekly Paclitaxel Carboplatin Induction is 'Effective and Well-Tolerated' in Platinum-Resistant Ovarian Cancer

Share this article:

(ChemotherapyAdvisor) – Dose-dense weekly paclitaxel/carboplatin can safely substitute for paclitaxel/cisplatin to reduce induction therapy–associated toxicity among patients diagnosed with progressive platinum-resistant epithelial ovarian cancer (EOC), report authors of a long-term analysis published in the European Journal of Cancer.

“Six cycles weekly paclitaxel/carboplatin followed by six 3-weekly cycles is well-tolerated and highly active in platinum-resistant and platinum-sensitive patients,” reported M.E.L. van der Burg and colleagues at Erasmus MC Rotterdam in Rotterdam, the Netherlands and the University Hospital Leuven, in Belgium.

After 3-weekly paclitaxel/carboplatin, patients with EOC were treated with six cycles weekly paclitaxel (90 mg/m2) and carboplatin AUC (area under the curve) 4 mg/mL/min, followed by six cycles 3-weekly paclitaxel/carboplatin, the authors reported.

“Median progression free survival (PFS) after last platinum was 9 months (range, 0-81 months) in 108 patients; 43 were platinum-resistant, of whom 13 started weekly paclitaxel/carboplatin less than 6 months after progression,” the authors reported. “During 533 weekly cycles, grade 3/4 toxicity included: thrombocytopenia 8%, neutropenia 30%, febrile neutropenia 0.5%. Nonhematologic toxicity was low. Treatment was delayed in 16% and dose reduced in 2% of cycles.”

Median PFS was 8  months (range, 1-21 months) and 13 months (range, 1-46 months) for platinum-resistant and platinum-sensitive patients, respectively. Median overall survival (OS) was 15 (range, 1-69) and 26 (range, 4-93) months, respectively.

“The 13 platinum-resistant patients with a platinum-therapy free interval less than 6 months had a significantly shorter PFS (4 vs. 10 months; P=0.035) and OS (9 vs. 15 months, P=0.002),” the authors noted. “The platinum therapy-free interval seemed to be a good criterion to select poor-risk, platinum-resistant patients.”


Share this article:

Related Resources

You must be a registered member of Chemotherapy Advisor to post a comment.

Sign Up for Free e-newsletters

Enter Our April Contest

Start the contest today

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gynecologic Cancer

High-volume Centers Have Higher Gynecologic Cancer Survival

High-volume Centers Have Higher Gynecologic Cancer Survival

Survival advantage of 2.3 to 34.1 months for treatment at highest- versus lowest-volume centers.

BRCA Mutation Risk Underestimated by BRCAPRO Model

BRCA Mutation Risk Underestimated by BRCAPRO Model

More mutations observed than expected at BRCAPRO scores of less than 40%.

FDA Panel Recommends HPV Test That Could Replace Pap

FDA Panel Recommends HPV Test That Could Replace ...

Experts voted 13-0 that Roche's test was safe and effective as first step in cervical cancer screening.